

Tumors in the body of a patient are studied *in situ* by a monitor (12), such as computer assisted tomography, X-ray or the like, while optimal flow paths through the tumor area are established. A catheter (52) with a suction lumen (50) and an infusion lumen (25), with seals (22, 56) associated with each, is placed in the patient's vein near the tumor. Flow is then sealed in the vein with the infusion seal (56). A carrier medium dye is injected into the tumor at selected flow rates and differential pressures. Flow of the dye through the tumor is observed on the monitor (12) to determine optimal retrograde perfusion paths through the tumor for the selected flow rates and differential pressures. Once the optimal perfusion paths are noted, microspheres with active ingredients, such as chemotherapy, can be selectively perfused through each of the paths in the tumor at desired flow rates, pressures and active ingredient dosages.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland				

-1-

Title: IMPROVED RETROGRADE PERFUSION

Specification

Background of Invention

Field of Invention:

The present invention relates to treatment of tumors.

Description of Prior Art:

5 In the conventional treatment of a solid tumor, the
state of the art lies in arterial infusion, a one-way
process which comprises a single pass of a
chemotherapeutic agent via the arterial side of the body
through the tumor. The principal drawback to this method
10 is the inability to maintain the dose rate and/or duration
of exposure of a drug necessary to effect a response, due
to the resulting systemic toxicity. That is, with present
methods, the successful treatment of a solid tumor with
chemotherapy is undermined by leakage of the chemotherapy
15 which proves detrimental to the remainder of the body.

Routine blood flow originates in the heart and
progresses in an arterial to capillary to venous sequence.
The walls of the post-capillary venules, capillaries, and
sinusoids are exchange vessels, serving as the site of

exchange between the blood and the tissue bathing the cells. The larger venules and veins comprise a system of capacitance or reservoir vessels. These are large-volume, low-pressure vessels through which the cardiac (right side
5 of the heart) return occurs.

Under normal conditions, the endothelial cells that form the lining of the vascular network renew themselves very slowly. According to Folkman, in an article entitled "The Vascularization Of Tumors," Scientific American, June
10 1976 (p.71), "Occasionally there is a brief burst of proliferative activity in one part of the vascular system when such activity is needed to heal a wound or mount an immune response. However, the new vessels always regress after a short time, and regenerative activity subsides to
15 its former low state." The cells proliferate rapidly where needed for the purpose of immunity as of healing wounds. However, such proliferation is maintained only as long as necessary. Thereafter, regenerative activity resumes its former state.

Blood circulation to a solid tumor likewise flows routinely from arterial to capillary to venous. However, in the topographical region between the exchange vessels and the larger venules, the direction of flow changes dramatically. Folkman explains what occurs: "When a
25 malignant tumor sends out its chemical message, the proliferation of endothelial cells rises steeply in the vicinity of the tumor. Capillaries bud from the side walls of venules and lengthen into thin tubes, converging on the tumor from all directions." This characteristic of
30 the tumor vessels results in the creation of numerous venous-venous (V-V) shunts, which are the physical elements that underlie the process of retrograde perfusion. The significance of the V-V shunts in the treatment of tumors is explained as follows.

35 The normal driving pressure in the tumor vasculature is the change in velocity of the blood flowing from the capillary into the venous system by means of the

cross-sectional area ($V \times A_{\text{capillaries}} = V \times A_{\text{venous}}$). That is, the pressure drop across these V-V channels is created by the change in velocity of the blood flow as it emerges from the capillaries. The tumor blood flow is thus impaired, measuring only two to fifteen percent of that of the surrounding tissue, and this impaired circulation distinguishes the cancer vasculature. The probability of blood flow through the V-V shunts is far less than the probability of blood flow through the normal vasculature. Therefore, in any attempt to deliver chemotherapy to a tumor, the likelihood that the drug will spread to the remainder of the body is far greater than the likelihood that it will reach the tumor.

Systemic toxicity resulting from chemotherapeutic regimens remains an obstacle to the successful treatment of cancer. In 1961, Stehlin, et al. identified leakage of the chemotherapeutic agent into the systemic circulation as "one of the most serious limitations as to the success of perfusion of certain regions of the body." As recently as March, 1981, the Journal of the American Medical Association featured an article by Kato, et al. and a related editorial by Chuang addressing chemoembolization, which is the "combination of arterial infusion of a chemotherapeutic agent and arterial embolization of the vascular supply to a neoplasm." This method produced a prolonged survival rate; however, the dosage rate was limited by systemic toxic effects. Similarly, in all of the techniques outlined by Fewer, Wilson and Lewis, the outflow returning to the venous system was left unaltered, resulting in systemic toxicity and a failure to maintain the needed duration of exposure of the drug. Dosage rate is another critical factor in cancer chemotherapy. Evidence supports the conclusion that maintenance of high doses of anti-tumor therapy substantially increases the response rate. This can be noted in marrow transplants, isolation infusion, or regional perfusion studies. Yet, arterial perfusion and infusion into the solid mass tumors

have demonstrated that the first passage of the drug in those methods is the only advantage over intravenous (IV) injection; thereafter toxicity remains the same.

Summary of the Invention:

5 Briefly, the present invention provides a new and improved method and apparatus for treating a tumor in the body of a patient with a chemotherapeutic agent. It is done by retrograde perfusion of the type described and disclosed in Applicant's prior co-pending U.S. Patent
10 Application Serial No. 871,528.

The present invention is illustratively described as comprising two catheter lumen with extensive maneuverability along with at least two controlled injectors as well as pumps, filters, analyzers, and other
15 suitable means for regulating and monitoring the outflow draining from the tumor. The initial step is to take an arteriogram which yields a graphic representation of the internal loops within the blood flow and aids in determining the preferential drainage. The perfusion
20 process begins with retrograde insertion of a catheter with lumens into the preferential drainage of a solid tumor via an external vein.

The catheter has a suction lumen and an infusion lumen extending beyond the suction lumen and is located in
25 a vein of a patient near the tumor. An infusion seal is located on the catheter between the infusion lumen and the suction lumen, while a suction seal is located on the catheter to seal flow in the patient's vein past the suction lumen. The infusion lumen marks the site of entry
30 of the treatment agent and provides access to the V-V shunt. The second, or suction, lumen, is placed distally and has the suction capacity necessary to accommodate the therapeutic input, the arterial blood flow, the venous and lymphatic drainage, and the preferential drainage. Next,
35 with the catheters in position; retrograde emboli are placed in critical areas of the vasculature to inhibit leakage.

Over the catheter has been determined to be properly placed by a suitable monitor, a carrier medium which is observable on the monitor is injected into the tumor from the infusion lumen. According to the present invention, the carrier medium is injected at selected flow rates and pressures into the tumor and carrier medium progress through the tumor toward the suction lumen noted on the monitor. Preferential flow paths through the tumor which are formed at certain established flow rates and pressures are noted.

The catheter lumens placed within the tumor preferential drainage as described above form a third in-vivo space in addition to the first (cells) and second (interstitial spaces around the cells) in-vivo spaces. It is here that the procedure differs from previous methods.

An active ingredient, such as a chemotherapeutic agent is then injected into the tumor at one of the established flow rates and pressures so that the agent follows one of the preferential flow paths. The flow rate and pressure of injection may then be changed to another set of established valves to cause the chemotherapeutic agent to follow a new preferential flow path or paths through the tumor. Alternatively, the chemotherapeutic agent may be changed so that different treatment agents may be sent through the tumor along different preferential flow paths.

Within the selected areas of an organ chosen for perfusion, feedback loops have been formed with exterior access to a monitoring system which monitors pressure, concentration, temperature, time, and other variables to insure that systemic toxicity is avoided, that an appropriate dose rate of a particular one of the range of active ingredients is maintained, and that the integrity of the organ is not violated. As the drug is perfused through the solid tumor, it is bio-transformed responsive to the conditions of at least one and preferably all three of the body, the tumor, and the spent drug itself. Next, it is led out of the body via the suction catheter to be

filtered and analyzed by suitable filter and analyzer means. Then, the process is repeated as often as necessary until the desired steady state is achieved. Retrograde perfusion according to the present invention thus provides a treatment technique which succeeds in effect in establishing the clinician as an element of the tumor vasculature. From this vantage point, the clinician is able to interact with the tumor and see what the possibilities of interaction are, becoming a monitor of the tumor's evolutionary process and thus capable of disrupting the homeostatic inertia of the tumor, creating a feedback system with virtually unlimited interaction possible.

A different active ingredient can subsequently be introduced along the same established flow path, or the lumens and emboli moved to other locations in the tumor where flow paths have been noted to be capable of being established. The same or different active ingredients may then be infused through the tumor along the new flow path and the procedure repeated. The procedure is continued for each flow path established until treatment is completed.

The present invention is characterized by three features commonly lacking in previous methods of treatment. First, previous methods fail to change the basic pattern of the established blood flow in the tumor. Second, previous methods allow the established cancer cells to persist, never interrupting the homeostatic inertia of the tumor. Finally, because previous methods lack the capability of interacting with the tumor, they are incapable of controlling the flow pattern and thus the duration of exposure, dose rate, preferential drainage, leakage factor, and level of toxicity which are crucial in the successful treatment of cancer.

One advantage of the present method is that it recognizes the significance of the V-V shunt, but no longer treats vascular flow through the V-V shunt as a

substrate limited process. The physical structure of the tumor vasculature is a limiting factor in the delivery of chemotherapy. By the nature of their location beyond the pre-capillary sphincter and the capillary beds, the

5 V-V shunts can be perfused only randomly by present methods -- concentration, duration of exposure, in short, bioavailability of chemotherapy is random. With retrograde perfusion it will no longer be necessary to reckon with the impaired circulation through the tumor,

10 for the new method will enable the clinician to provide chemotherapy at a pressure rate needed to drive the flow backward through the flow paths created in the tumor vasculature. Because the flow paths are created such that leakage sites are blocked, systemic toxicity is avoided,

15 yet adequate levels of chemotherapy are certain to reach the tumor.

A second advantage of retrograde perfusion is that it recognizes the importance of tumor progression, which is the steady increase in malignancy characteristic of

20 vascularized tumors. According to Folkman, tumor progression is a result of the rapid increase in cell division cause by vascularization. As cells proliferate over a period of time, they at first metastasize, then invade surrounding tissue, and finally, appear as ascites

25 cells in the host's abdominal cavity. The present method appreciates the different stages of tumor progression and allows the clinician to intervene selectively at the appropriate time with the appropriate combination of dose rate, concentration, pressure, duration of exposure, and

30 other factors which will inhibit vascularization with subsequent tumor growth.

The dose response curve of chemotherapeutic agents is well known; the more effective the drug, the steeper the curve. Presently, dose response is measured by three

35 criteria -- reduction in tumor mass, increased survival, or bioassay methods. A third advantage of retrograde perfusion is that it permits optimum assessment of the

steep dose response curve, particularly by the bioassay method. By closely tracking the dose response, every effort is made to eliminate the deflection point which represents tumor growth and decreased patient survival.

5 Another advantage of the present method is that it virtually separates the tumor from the body. Division of the tumor load from the host provides opportunities in several ways. It heightens the immune system; it eliminates the single pass of chemotherapy typical of
10 arterial perfusions; it provides constant contact of the chemotherapeutic agent within the tumor vessels, which is particularly useful with a radio-sensitizing agent; and it facilitates delivery of a radioactive slurry via the catheter system. Furthermore, the chemotherapy can be
15 calculated on the basis of tumor burden rather than being limited by the effects of the systemic toxicity, and the concentric catheters can be utilized as an access point for hyperalimentation to induce patient well-being.

Brief Description of the Drawings:

20 Fig. 1 is an isometric view of a patient undergoing treatment according to the present invention.

Fig. 2 is a schematic view of an apparatus according to the present invention; and

25 Figs. 3, 3A, 4, 4A, 5 and 5A are enlarged schematic views of a kidney being treated according to the present invention.

Description of the Preferred Embodiment:

According to the present invention, a double balloon concentric catheter system C (Figs. 1 and 2) is used to
30 treat a person. The catheter C is used for retrograde perfusion of a patient's body, by which is meant that an agent is injected into the patient's venous system in a direction counter to normal blood flow. The retrograde injected agent then perfuses a portion of the body being
35 treated via the venous system.

In a preferred embodiment, the catheter system C is used to inject and retrograde perfuse one or more active

ingredients, such as monoclonal antibodies, lymphokines or differentiation factors, through a solid tumor at selected times in such a way that variables, such as the tidal concentration, duration of exposure and systemic toxicity may be controlled. As will be set forth in detail below, the active ingredients may be introduced along the same or different flow paths established through the tumor according to the present invention.

During treatment according to the present invention, the patient's response and reactions are observed and monitored by a monitor, such as computerized axial tomography (CAT) scanner 10 (Fig. 1) and a video monitor 12, using two double balloon concentric catheters 14 and 16. The double balloon concentric catheters 14 and 16 according to the present invention include an inner tube or infusion lumen 18 (Fig. 6) encircled near an end or tip 20 by an infusion seal or inflatable balloon 22 which is used to seal a patient's vein in which the lumen 18 is placed. The catheters 14 and 16 are shown in somewhat simplified form in Fig. 2 in order that structural features may more clearly be seen. The infusion lumen 18 is used on insertion to direct the flow of the therapeutic input fluid through vessels in the portion of the body being treated. As is usual, a guide wire 24 is provided in the end 20 of lumen 18 to assist in insertion and movement to the desired location in the patient's venous system. The guide wire 24 is withdrawn once the lumen 18 is properly positioned.

Driving power for the infusion lumen 18 is provided by a syringe injector 26 with push/pull capacity to insert and withdraw the lumen 18 which aids in establishing feedback loops of multiple flow paths beginning in the tumor vessels and extending outside the body. This makes it possible to control the concentration, flow rate, differential pressure, temperature, and time duration of active ingredient input. In this manner systemic toxicity is avoided, appropriate dose rate of selected active

ingredients through established flow paths through the tumor are maintained, and the integrity of the organ is not violated. The infusion lumen 18 further includes an opening passage 25 in the end 20, forming a site of entry of either a carrier medium or an active ingredient into the patient's vein. The infusion lumen 18 may have an additional passageway or lumen 30 formed therein which may be used for either infusion or suction purposes. A port is located within an area encircled by the inflatable balloon 22 to allow inflation of the balloon 22 as desired for sealing the veins and directing the flow of fluids. A port 31 may be formed, if desired, in the lumen 18 as an inlet to lumen 30 behind the inflatable balloon 22 to permit injection or extraction of fluid from the patient's vein.

The catheter system 14 further includes an injection system 32 including a flow path injector 34 and treatment injector 36 selectively placed in fluid communication with infusion lumen 18 via valve 38a. The flow path injector 34 includes a container 40 for a suitable carrier medium from container 40, when connected via valve 38a into the patient's vein via infusion lumen 18. The flow path injector 34 may be, for example, a Model 510 Mark V injection system of the type sold by MEDRAD, Inc. of Pittsburgh, Pennsylvania.

The treatment injector 36 includes a first container 44 for a first active ingredient of the type set forth above and a second container 46 for a second active ingredient of the type set forth above. The active ingredients in containers 44 and 46 are typically transported on microspheres, and the flow and dosage rate and application pressure into the patient's vein via infusion lumen 18, when connected via valve 38a, is controlled by an injector control 48. The treatment injector 36 may be, for example, a Model 570 Mark V injection system of the type sold by MEDRAD, Inc. of Pittsburgh, Pennsylvania.

A port 50 in a suction lumen 52 collects either return carrier medium or partially or wholly spent active ingredient, depending on which is being infused, in a collector syringe 54 after it has been retrograde perfused through the tumor vessels, as hereinafter set forth. The infusion lumen 18 is preferably concentrically mounted in the suction lumen 52 which functions to transport the collected fluids outside the body to collection syringe 54, from which such fluids may be transferred to a suitable filter for filtration purposes. The filtered, toxic-free active ingredient may then be stored or alternatively re-injected into the veins via port 25.

The suction lumen 52 of the present invention also includes a suction seal or balloon 56 which is inflatable in the patient's vein via a port to seal the vein, blocking the flow of infused fluids from the injection lumen 18 to the remainder of the patient's body. Motive power for the suction lumen 52 is provided by a syringe injector 58 with push/pull capacity to insert and withdraw the lumen 52 during establishment and utilization of multiple flow paths through the tumor.

Lumens 18 and 52 are jointed and made common at a T-junction or side arm 60. Similarly, the fluid passage to syringe 26 and injector system 32 branch and remain separate so their fluids do not mix at a side arm 62, while a side arm 64 branches the fluid passages to syringes 54 and 58, keeping their respective fluids separate and distinct. The syringe 54 is connected to the side arm 64 by a connecting-Tee 66.

The process of improved retrograde perfusion according to the present invention is performed by inserting the infusion lumen 18 and suction lumen 52 through the patient's vein to a location near the tumor, shown in the drawings (Fig. 3, for example) as in a kidney 70. The infusion seal 22 is inflated to block the patient's vein and carrier medium is fed from container 40 at a selected flow rate by injector control 42 into the

tumor through infusion lumen. The suction lumen 52 may be located very near the infusion seal 22 and suction seal 56 left uninflated during initial carrier medium injection. Alternatively, it may be moved to one of several sites in the tumor (Figs. 3, 4 and 5) and suction seal 56 inflated.

In either situation, the flow rate of injection of carrier medium from container 40 and pressure differential between infusion lumen 18 and suction seal 56 may be varied. Monitor 12 is then used to observe passage of carrier medium through the tumor for various flow rates, pressure differentials and lumen locations.

Usually, one or more flow paths (Fig. 3, 4 and 5) are formed through the kidney 70 for selected infusion conditions, indicated by flow lines 72 (Fig. 3), 74 (Fig. 4) and 76 (Fig. 5).

The lumens 18 and 52 are then moved into a first one of the selected infusion positions in the kidney 70 (Fig. 3) and the seals 22 and 56 inflated. A first active ingredient, such as from container 44, is then infused under control of injector control 48 at a desired flow and dosage rate and differential pressure along a first one of the preferential flow paths, as indicated by symbols 78, between infusion lumen 18 and suction lumen 52. The active ingredient, whether fully or partially spent, is passed via suction lumen 52 to collector syringe 56 for treatment in the manner set forth above.

After treatment of the tumor along the first preferential flow path, the relative position of lumens 18 and 52 is then adjusted by moving the suction lumen 52 and seal 56 further away from the infusion lumen 18 and seal 22 in the tumor to a location (Fig. 4) where another preferential flow path through the kidney 70 was established for a particular flow rate and differential pressure. At the next location, the active ingredient from container 46, as indicated by symbols 80 (Fig. 4A) may be infused at a desired flow and dosage rate through the tumor. Alternatively, the active ingredient from container 44 may be used again.

After treatment along the second flow path, lumens 18 and 52 may again be adjusted in relative position (Fig. 5) to another location where another preferential flow path was noted. Active ingredient is then infused at the noted pressures and flow and dosage rates for this flow path using either active ingredient from container 44 as indicated by symbols 78 (Fig. 5A) or from container 46 as treatment needs indicate.

One or more of the established flow paths through the tumor may be used to infuse different active ingredients according to a treatment regimen. Alternatively, all established flow paths may be used for infusion of the same active ingredient. In this manner, the flow patterns of active ingredients through the tumor, the type of active ingredients, dosages, preferential drainage and the like may be adjusted as the progress of the treatment is noted. Separation of the tumor load from the body and formation of several preferential flow paths through the tumor in this manner creates a treatment procedure wherein the clinician may freely act upon and interact with the tumor.

The foregoing disclosure and description of the invention are illustrative and explanatory thereof, and various changes in the size, shape and materials, as well as in the details of the illustrated construction may be made without departing from the spirit of the invention.

CLAIMS:

1 1. An apparatus for treating a tumor in the body of
2 a patient with an active ingredient, comprising:

3 (a) catheter means for location in a vein of
4 the patient near the tumor, said catheter means
5 comprising:

6 (1) a suction lumen; and

7 (2) an infusion lumen extending beyond
8 said suction lumen;

9 (b) infusion seal means on said catheter means
10 between said infusion lumen and said suction lumen;

11 (c) suction seal means on said catheter means
12 for sealing the flow of fluid in the patient's vein past
13 said suction lumen;

14 (d) flow path means for injecting a carrier
15 medium into the tumor from the infusion lumen at selected
16 flow rates and pressures to establish preferential flow
17 paths through the tumor;

18 (e) treatment means for injecting an active
19 ingredient into the patient's vein from said infusion
20 lumen at one of the selected flow rates and pressures so
21 that the active ingredient may perfuse through the tumor
22 along one of the preferential flow paths established by
23 said flow path means; and

24 (f) means for collecting the active ingredient
25 from said suction lumen after perfusion through the tumor.

1 2. The apparatus of Claim 1, wherein said treatment
2 means further comprises:

3 means for varying the flow rate and pressure of
4 injection of the active ingredient into the patient's
5 tumor to establish distinct differential flow paths
6 therethrough.

1 3. The apparatus of Claim 1, wherein said treatment
2 means further comprises:

1 means for selectively injecting different active
2 ingredients into the patient's vein at different flow
3 rates and pressures so that the different active
4 ingredients may perfuse through the tumor along distinct
5 preferential flow paths.

1 4. The apparatus of Claim 1, wherein said treatment
2 means further comprises:

3 means for selectively injecting different active
4 ingredients into the patient's vein at different flow
5 rates and pressures so that the different active
6 ingredients may perfuse through the tumor along distinct
7 preferential flow paths at different times.

1 5. The apparatus of Claim 1, further including:
2 means for selectively connecting said flow path
3 means and said treatment means to said suction lumen.

1 6. The apparatus of Claim 1, further including:
2 means for analyzing the collected active
3 ingredient.

1 7. The apparatus of Claim 1, further including:
2 means for filtering the collected active
3 ingredient.

1 8. The apparatus of Claim 1, further including:
2 means for re-injecting the filtered active
3 ingredient into the vein of the patient.

1 9. A method for treating a tumor in the body of a
2 patient with an active ingredient, comprising the steps
3 of:

4 (a) placing a catheter having a suction lumen
5 and an infusion lumen extending beyond the suction lumen
6 and a seal associated with each of such lumens in a vein
7 of the patient near the tumor;

1 (b) sealing the flow of fluid in the patient's
2 vein between the infusion lumen and the suction lumen with
3 the infusion seal;

4 (c) injecting a carrier medium into the tumor
5 from the infusion lumen at selected flow rates and
6 pressures to establish preferential flow paths through the
7 tumor;

8 (d) sealing the flow of fluid in the patient's
9 vein past the suction lumen with the suction seal;

10 (e) injecting an active ingredient into the
11 patient's vein from the infusion lumen at one of the
12 selected flow rates and pressures so that the active
13 ingredient may perfuse through the tumor along one of the
14 preferential flow paths established during said step of
15 injecting; and

16 (f) collecting the active ingredient in the
17 suction lumen after perfusion through the tumor.

1 10. The method of Claim 9, further including the
2 step of:

3 collecting the injected carrier medium after
4 said step of injecting same.

1 11. The method of Claim 10, wherein:

2 said step of collecting the carrier medium is
3 performed after said step of sealing the flow of fluid
4 past the suction lumen.

1 12. The method of Claim 11, wherein:

2 said step of collecting the carrier medium
3 comprises collecting the carrier medium in the suction
4 lumen.

1 13. The method of Claim 12, further including the
2 step of:

3 moving the suction lumen to different positions
4 in the patient's tumor for each of the selected flow rates

1 and pressures to conform to the flow paths established
2 through the tumor.

1 14. The method of Claim 10, wherein:
2 said step of collecting the carrier medium is
3 performed after said step of sealing the flow of fluid
4 past the suction lumen.

1 15. The method of Claim 9, further including the
2 steps of:
3 varying the flow rate and pressure of injection
4 of the active ingredient into the patient's tumor to
5 establish distinct differential flow paths therethrough.

1 16. The method of Claim 9, further including the
2 steps of:
3 selectively injecting different active
4 ingredients into the patient's vein at different flow
5 rates and pressures so that the different active
6 ingredients may perfuse through the tumor along distinct
7 preferential flow paths.

1 17. The method of Claim 9, further including the
2 steps of:
3 selectively injecting different active
4 ingredients into the patient's vein at different flow
5 rates and pressures so that the different active
6 ingredients may perfuse through the tumor along distinct
7 preferential flow paths at different times.

1 18. The method of Claim 9, further including the
2 step of:
3 analyzing the collected active ingredient.

1 19. The method of Claim 9, further including the
2 step of:
3 filtering the collected active ingredient.

- 1 20. The method of Claim 19, further including the
- 2 step of:
- 3 re-injecting the filtered active ingredient into
- 4 the vein of the patient.

1/8




FIG. 1

SUBSTITUTE SHEET

2/8





FIG. 2


SUBSTITUTE SHEET

FIG. 3




4/8

FIG. 3A



5/8

FIG. 4



SUBSTITUTE SHEET

6/8

FIG. 4A





FIG. 5



INTERNATIONAL SEARCH REPORT

International Application No. PCT/US88/02692

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC IPC(4) : A61B 1/06 U.S. Cl.: 604/28																				
II. FIELDS SEARCHED <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Minimum Documentation Searched ⁷</div> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 20%; border: 1px solid black;">Classification System</th> <th style="border: 1px solid black;">Classification Symbols</th> </tr> <tr> <td style="border: 1px solid black; vertical-align: top;">US</td> <td style="border: 1px solid black; vertical-align: top;"> 128/328, 334R, 654-656, 658; 600/3; 604/4, 8, 9, 27, 28, 35, 38, 40, 41, 43, 49, 52, 53, 93, 96, 101, 118 121, 151, 264, 284 </td> </tr> </table> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸</div>			Classification System	Classification Symbols	US	128/328, 334R, 654-656, 658; 600/3; 604/4, 8, 9, 27, 28, 35, 38, 40, 41, 43, 49, 52, 53, 93, 96, 101, 118 121, 151, 264, 284														
Classification System	Classification Symbols																			
US	128/328, 334R, 654-656, 658; 600/3; 604/4, 8, 9, 27, 28, 35, 38, 40, 41, 43, 49, 52, 53, 93, 96, 101, 118 121, 151, 264, 284																			
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹ <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 10%; border: 1px solid black;">Category *</th> <th style="border: 1px solid black;">Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²</th> <th style="width: 15%; border: 1px solid black;">Relevant to Claim No. ¹³</th> </tr> <tr> <td style="border: 1px solid black; text-align: center; vertical-align: top;">X</td> <td style="border: 1px solid black; vertical-align: top;"> US, A 2,854,982 (PAGANO) 07 OCTOBER 1958 See Col. 2, lines 16-24, 45-51; column 3, line 27 - column 4 line 3 </td> <td style="border: 1px solid black; text-align: center; vertical-align: top;">1-4, 8</td> </tr> <tr> <td style="border: 1px solid black; text-align: center; vertical-align: top;">A</td> <td style="border: 1px solid black; vertical-align: top;"> US, A 3,888,239 (RUBINSTEIN) 10 JUNE 1975 See column 2, line 54 thru column 3, line 7; column 7, lines 1-11 </td> <td style="border: 1px solid black;"></td> </tr> <tr> <td style="border: 1px solid black; text-align: center; vertical-align: top;">A</td> <td style="border: 1px solid black; vertical-align: top;"> US, A 4,192,302 (BODDIE) 11 MARCH 1980 See column 1, lines 11-21, 27-30; column 2, line 13 thru column 3, line 68 </td> <td style="border: 1px solid black;"></td> </tr> <tr> <td style="border: 1px solid black; text-align: center; vertical-align: top;">X</td> <td style="border: 1px solid black; vertical-align: top;"> US, A 4,445,892 (HUSSEIN ET AL) 01 MAY 1984 See Figures 4-6; column 1, line 65 thru column 2, line 27; column 5, line 66 thru column 7, line 10 </td> <td style="border: 1px solid black; text-align: center; vertical-align: top;">1-4, 8</td> </tr> <tr> <td style="border: 1px solid black; text-align: center; vertical-align: top;">Y, P</td> <td style="border: 1px solid black; vertical-align: top;"> US, A 4,708,718 (DANIELS) 24 NOVEMBER 1987 See column 3, lines 51-63; column 6, lines 46-55 </td> <td style="border: 1px solid black; text-align: center; vertical-align: top;">1-4, 6-12, 14, 18-20</td> </tr> </table>			Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	X	US, A 2,854,982 (PAGANO) 07 OCTOBER 1958 See Col. 2, lines 16-24, 45-51; column 3, line 27 - column 4 line 3	1-4, 8	A	US, A 3,888,239 (RUBINSTEIN) 10 JUNE 1975 See column 2, line 54 thru column 3, line 7; column 7, lines 1-11		A	US, A 4,192,302 (BODDIE) 11 MARCH 1980 See column 1, lines 11-21, 27-30; column 2, line 13 thru column 3, line 68		X	US, A 4,445,892 (HUSSEIN ET AL) 01 MAY 1984 See Figures 4-6; column 1, line 65 thru column 2, line 27; column 5, line 66 thru column 7, line 10	1-4, 8	Y, P	US, A 4,708,718 (DANIELS) 24 NOVEMBER 1987 See column 3, lines 51-63; column 6, lines 46-55	1-4, 6-12, 14, 18-20
Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³																		
X	US, A 2,854,982 (PAGANO) 07 OCTOBER 1958 See Col. 2, lines 16-24, 45-51; column 3, line 27 - column 4 line 3	1-4, 8																		
A	US, A 3,888,239 (RUBINSTEIN) 10 JUNE 1975 See column 2, line 54 thru column 3, line 7; column 7, lines 1-11																			
A	US, A 4,192,302 (BODDIE) 11 MARCH 1980 See column 1, lines 11-21, 27-30; column 2, line 13 thru column 3, line 68																			
X	US, A 4,445,892 (HUSSEIN ET AL) 01 MAY 1984 See Figures 4-6; column 1, line 65 thru column 2, line 27; column 5, line 66 thru column 7, line 10	1-4, 8																		
Y, P	US, A 4,708,718 (DANIELS) 24 NOVEMBER 1987 See column 3, lines 51-63; column 6, lines 46-55	1-4, 6-12, 14, 18-20																		
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>* Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>																				
IV. CERTIFICATION <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; border: 1px solid black; vertical-align: top;"> Date of the Actual Completion of the International Search 26 October 1988 </td> <td style="width: 50%; border: 1px solid black; vertical-align: top;"> Date of Mailing of this International Search Report <div style="font-size: 1.5em; font-weight: bold; text-align: center;">05 DEC 1988</div> </td> </tr> <tr> <td style="border: 1px solid black; vertical-align: top;"> International Searching Authority ISA/US </td> <td style="border: 1px solid black; vertical-align: top;"> Signature of Authorized Officer <div style="text-align: center;"> Mario A. Costantino </div> </td> </tr> </table>			Date of the Actual Completion of the International Search 26 October 1988	Date of Mailing of this International Search Report <div style="font-size: 1.5em; font-weight: bold; text-align: center;">05 DEC 1988</div>	International Searching Authority ISA/US	Signature of Authorized Officer <div style="text-align: center;"> Mario A. Costantino </div>														
Date of the Actual Completion of the International Search 26 October 1988	Date of Mailing of this International Search Report <div style="font-size: 1.5em; font-weight: bold; text-align: center;">05 DEC 1988</div>																			
International Searching Authority ISA/US	Signature of Authorized Officer <div style="text-align: center;"> Mario A. Costantino </div>																			

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
Y,P	US,A 4,709,703 (LAZAROW ET AL) 01 DECEMBER 1987 See column 4, lines 6-12	1-4,6-12,14 18-20
&,P	US,A 4,714,460 (CALDERON) 22 DECEMBER 1987 See entire document. - Member of the same family as this PCT application.	1-4,6-12,14, 18-20
A	KATO et al; "Arterial Chemoembolization With Microencapsulated Anticancer Drug" JAMA; 20 March, 1981; Vol 245, No. 11 pages 1123-1127; See page 1124, column 1, lines 10-44	